Osimertinib Monotherapy (The FLAURA clinical trial):

Both progression-free and overall survival were longer with Osimertinib than with first-generation EGFR TKIs.

@JuliaRotow
#LungCancer #Osimertinib #EGFR #TKIs #TheFlauraClinicalTrial